Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H R Brunner

Showing results (491-500 of 564) with videos related to

Pageof 57
Sort By:
Journal of Cardiovascular Pharmacology|June 1, 1995
Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin IN Inglessis, J Nussberger, M Hagmann, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|August 1, 1992
Arterial dilatory reserve in congestive heart failureR Zelis, D Hayoz, H Drexler, et al.
Annales Francaises D'Anesthesie Et De Reanimation|January 1, 1989
[Effects of clonidine on tourniquet-induced systemic arterial hypertension in general anesthesia]P Y Erard, J P Gardaz, J Nussberger, et al.
American Journal of Hypertension|September 1, 1989
Effect of cold pressor test on the internal diameter of the radial arteryF Perret, V Mooser, B Waeber, et al.
The Journal of Clinical Investigation|December 19, 2001
Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2C Pellieux, A Foletti, G Peduto, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1988
Effects of a nonpressor dose of neuropeptide Y on cardiac output, regional blood flow distribution and plasma renin, vasopressin and catecholamine levelsJ F Aubert, M Burnier, B Waeber, et al.
British Journal of Clinical Pharmacology|January 1, 1979
Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertensionH R Brunner, H Gavras, B Waeber, et al.
Journal of Cardiovascular Pharmacology|January 1, 1987
Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical modelR J Francis, A N Brown, L Kler, et al.
The American Journal of Cardiology|September 20, 1973
Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidoneE D Vaughan, J H Laragh, I Gavras, et al.
The Journal of Clinical Endocrinology and Metabolism|December 12, 2001
NPY regulates catecholamine secretion from human adrenal chromaffin cellsC Cavadas, A P Silva, F Mosimann, et al.
Pageof 57

Showing results (491-500 of 564) with videos related to

Sort By:
Pageof 57
Journal of Cardiovascular Pharmacology|June 1, 1995
Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin IN Inglessis, J Nussberger, M Hagmann, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|August 1, 1992
Arterial dilatory reserve in congestive heart failureR Zelis, D Hayoz, H Drexler, et al.
Annales Francaises D'Anesthesie Et De Reanimation|January 1, 1989
[Effects of clonidine on tourniquet-induced systemic arterial hypertension in general anesthesia]P Y Erard, J P Gardaz, J Nussberger, et al.
American Journal of Hypertension|September 1, 1989
Effect of cold pressor test on the internal diameter of the radial arteryF Perret, V Mooser, B Waeber, et al.
The Journal of Clinical Investigation|December 19, 2001
Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2C Pellieux, A Foletti, G Peduto, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1988
Effects of a nonpressor dose of neuropeptide Y on cardiac output, regional blood flow distribution and plasma renin, vasopressin and catecholamine levelsJ F Aubert, M Burnier, B Waeber, et al.
British Journal of Clinical Pharmacology|January 1, 1979
Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertensionH R Brunner, H Gavras, B Waeber, et al.
Journal of Cardiovascular Pharmacology|January 1, 1987
Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical modelR J Francis, A N Brown, L Kler, et al.
The American Journal of Cardiology|September 20, 1973
Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidoneE D Vaughan, J H Laragh, I Gavras, et al.
The Journal of Clinical Endocrinology and Metabolism|December 12, 2001
NPY regulates catecholamine secretion from human adrenal chromaffin cellsC Cavadas, A P Silva, F Mosimann, et al.
Pageof 57